The combination of ampicillin and sulbactam injection is used to treat certain infections caused by bacteria, including infections of the skin, female reproductive organs, and abdomen (stomach area). Ampicillin is in a class of medications called penicillin-like antibiotics. It works by stopping the growth of bacteria. Sulbactam is in a class of medications called beta-lactamase inhibitors. It works by preventing bacteria from destroying ampicillin.
This report contains market size and forecasts of Ampicillin and Sulbactam for Injection in global, including the following market information:
Global Ampicillin and Sulbactam for Injection Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Ampicillin and Sulbactam for Injection Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Ampicillin and Sulbactam for Injection companies in 2021 (%)
The global Ampicillin and Sulbactam for Injection market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
1.5g/vial Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Ampicillin and Sulbactam for Injection include Pfizer, Mylan, Meitheal Pharmaceuticals, Reyoung Pharmaceuticals, Sagent Pharmaceuticals, AuroMedics, Hikma Pharmacuticals, Piramal Critical Care and WG Critical Care and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Ampicillin and Sulbactam for Injection manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Ampicillin and Sulbactam for Injection Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Ampicillin and Sulbactam for Injection Market Segment Percentages, by Type, 2021 (%)
1.5g/vial
3g/vial
Global Ampicillin and Sulbactam for Injection Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Ampicillin and Sulbactam for Injection Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Others
Global Ampicillin and Sulbactam for Injection Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Ampicillin and Sulbactam for Injection Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Ampicillin and Sulbactam for Injection revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Ampicillin and Sulbactam for Injection revenues share in global market, 2021 (%)
Key companies Ampicillin and Sulbactam for Injection sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Ampicillin and Sulbactam for Injection sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Mylan
Meitheal Pharmaceuticals
Reyoung Pharmaceuticals
Sagent Pharmaceuticals
AuroMedics
Hikma Pharmacuticals
Piramal Critical Care
WG Critical Care
Wellona Pharma